Amylx Pharmaceuticals Inc vs Cassava Sciences Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 55.3× Cassava Sciences Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | FLNA | |
|---|---|---|
Market Cap | $2.64B | $47.75M |
Sector | Health | Health |
52-Week High | $24.19 | $4.64 |
52-Week Low | $7.82 | $0.87 |
Enterprise Value | $2.39B | -$34.93M |
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →